[OCR skipped on page(s) 1]
aobbvie Adalimumab

Core Risk Management Plan
Version 16.2 / Data Lock Point 31 December 2021

Core Risk Management Plan for
Humira

AbbVie Inc. (AbbVie)

RMP version to be assessed as part of this application:
RMP Version Number: 16.2

Data lock point forthis RMP: 31 December 2021

Date of final sign off: September 2024

Rationale for submitting an updated RMP:

Removed Long Term Safety Information in the Treatment of Children with Uveitis from Missing
Information.

Reclassified Missing Information "Episodic treatment in Ps, UC and JIA" to "Episodic treatment
in UC"

Summary of significant changes in the RMP: A summary of significant changes is included in
RMP Annex 8.


[OCR skipped on page(s) 3]